Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2023-10-09
DOI
10.1080/14787210.2023.2268287
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies
- (2023) Yulong Chi et al. Expert Review of Anti-Infective Therapy
- Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams
- (2023) Milo Gatti et al. Expert Review of Anti-Infective Therapy
- Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy
- (2023) Jason A. Roberts et al. Expert Review of Anti-Infective Therapy
- Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020
- (2023) Morgan A Alford et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13
- (2023) George G Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020
- (2023) Heather J Adam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry
- (2023) George Zhanel et al. Journal of Global Antimicrobial Resistance
- CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy
- (2023) Ivan Gentile et al. International Journal of Antimicrobial Agents
- Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study
- (2023) Davide Fiore Bavaro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy
- (2022) Joseph P. Lynch et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Infections Due to Acinetobacter baumannii–calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options
- (2022) Joseph P. Lynch et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections
- (2022) Jesús Sojo-Dorado et al. JAMA Network Open
- The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante’s Forest Dark
- (2022) Pranita D. Tamma et al. JAMA Network Open
- New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
- (2022) Truc T. Tran et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Escalation of antimicrobial resistance among MRSA part 2: focus on infections and treatment
- (2022) Joseph P. Lynch et al. Expert Review of Anti-Infective Therapy
- Escalation of antimicrobial resistance among MRSA part 1: focus on global spread
- (2022) Joseph P. Lynch et al. Expert Review of Anti-Infective Therapy
- Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies
- (2021) Roberta Maria Antonello et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry
- (2021) George G. Zhanel et al. Journal of Global Antimicrobial Resistance
- Escalating Antimicrobial Resistance Among Enterobacteriaceae: Focus on Carbapenemases
- (2021) Joseph P. Lynch et al. EXPERT OPINION ON PHARMACOTHERAPY
- Real-life experience with ceftolozane/tazobactam in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry
- (2021) George G. Zhanel et al. Journal of Global Antimicrobial Resistance
- Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- (2021) Jaesh Naik et al. Infectious Diseases and Therapy
- Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
- (2021) Milo Gatti et al. Drug Design Development and Therapy
- A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients
- (2021) Yatin Mehta et al. Indian Journal of Critical Care Medicine
- Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon
- (2021) Tala Ballouz et al. Journal of Infection in Developing Countries
- Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections
- (2021) Tasneem A.K. Abdallah et al. Journal of Infection and Public Health
- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- (2020) Antonio Vena et al. CLINICAL INFECTIOUS DISEASES
- Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
- (2020) Kamal Hamed et al. Future Microbiology
- Real life experience with Ceftobiprole in a tertiary care hospital
- (2020) Emanuele Durante-Mangoni et al. Journal of Global Antimicrobial Resistance
- Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series
- (2020) Ebrahim Mahmoud et al. Infection and Drug Resistance
- Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies
- (2020) Roberta Maria Antonello et al. Antibiotics-Basel
- Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis
- (2020) Nuria Monteagudo-Martínez et al. Expert Review of Anti-Infective Therapy
- Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
- (2020) Rosario Cultrera et al. Antibiotics-Basel
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
- (2019) George G. Zhanel et al. DRUGS
- Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
- (2019) Thomas W. L. Scheeren et al. BMC INFECTIOUS DISEASES
- Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa
- (2019) Benoît Pilmis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Current clinical use of intravenous fosfomycin in ICU patients in two European countries
- (2019) C. Putensen et al. INFECTION
- Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1500 mg Infusion
- (2019) Urania Rappo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of MRSA in Canada from 2007 to 2016
- (2019) Kimberly A Nichol et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016
- (2019) Andrew J Denisuik et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007–16
- (2019) Alyssa R Golden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007–16
- (2019) Philippe R S Lagacé-Wiens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study
- (2019) George G Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–15
- (2018) James A Karlowsky et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study
- (2018) Andrew J Denisuik et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
- (2018) Abdulrahman Elabor et al. Open Forum Infectious Diseases
- In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16
- (2017) Andrew Walkty et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
- (2016) George G. Zhanel et al. DRUGS
- Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults
- (2016) Coleman Rotstein et al. Canadian Journal of Infectious Diseases & Medical Microbiology
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
- (2014) S. S. Awad et al. CLINICAL INFECTIOUS DISEASES
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
- (2014) Helen W. Boucher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistantStaphylococcus aureus
- (2013) Ahmed Hamed Salem et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
- (2012) George G Zhanel et al. Expert Review of Anti-Infective Therapy
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
- (2012) Susan C. Nicholson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- New Lipoglycopeptides
- (2010) George G. Zhanel et al. DRUGS
- Ceftobiprole
- (2009) George G Zhanel et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Ceftaroline
- (2009) George G. Zhanel et al. DRUGS
- Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
- (2009) G. G. Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started